Tickdelta is free for now. Sign up and get Pro free
4 paragraphs in Risk Factors of the 10-K filed Feb 24, 2026 with nothing like them in the 10-K filed Feb 25, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies: a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it. A paragraph most of them have is marked boilerplate. No line means no other company has one like it. This counts text; it does not say how serious a risk is.
•changes in trade policy applicable to the regions in which we do business, including changes in U.S. trade policies or the imposition of higher tariffs on products being shipped into and from the U.S.,
Read in the 10-K ↗
Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation.
We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The development and deployment of AI presents both risks and opportunities, and the implementation process could adversely impact the operations of our business as a whole. AI algorithms utilized in the deployment may be flawed or based on datasets that are biased or insufficient, and do not adequately take into account the underlying nature of our business. Failure to adequately train our employees during the deployment of AI could adversely impact our business or result in delays or errors in our offerings. Our competitiveness could also be negatively impacted by our failure to timely develop or deploy AI in our products and services, particularly if our competitors are successful in AI advancements in their products and services. The development of AI technology will require significant investment in resources and human capital and could increase our costs. There is uncertainty related to the legal and regulatory landscape surrounding rapidly evolving AI technologies, particularly in the areas of cybersecurity, intellectual property, and privacy and data protection. Failure to comply or appropriately respond to this developing landscape may result in increased legal liability, adverse regulatory action, or reputational damage.
Read in the 10-K ↗
We cannot predict the scope, timing, or impact of threatened U.S. tariffs on imports, the extent to which other countries may impose retaliatory trade restrictions, or the terms of future trade policy changes. Tariffs implemented during fiscal year 2025 increased our cost of revenue by approximately $25 million and reduced our gross margin by approximately $20 million, primarily affecting products manufactured in Europe for the U.S. market. While we have implemented mitigation strategies including manufacturing optimization, supplier collaboration, pricing adjustments, and temporary cost measures, these actions may not fully offset the impact of existing or future tariffs. Additional tariffs or trade restrictions may materially and adversely affect our results of operations, financial condition, and competitive position.
Read in the 10-K ↗
11 paragraphs in the 10-Q filed Nov 10, 2026 with nothing like them in the 10-Q filed Aug 11, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
During the third quarter of fiscal year 2026, the Company entered into a definitive agreement to acquire Human Cell Design (“HCD”) for € 45.0 million (approximately $ 52.3 million) in cash consideration and up to € 8.0 million (approximately $ 9.3 million) in contingent consideration to be paid in cash based on the achievement of certain revenue metrics over a two-year period. HCD is a biotechnology company based in Toulouse, France specializing in human cell models and preclinical research solutions for diabetes, obesity and other metabolic diseases. The transaction is expected to close in the fourth quarter of fiscal year 2026 and is subject to customary closing conditions, including required regulatory approvals.
Read in the 10-Q ↗
Definitive agreement to dispose China Immunodiagnostics signed in fiscal year 2026
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
Three Months Ended Nine Months Ended October 4, September 28, October 4, September 28,
Read in the 10-Q ↗
2026. If we continue to repurchase shares, the Repurchase Program will be funded using our existing financial resources, including cash and cash equivalents, and our existing senior unsecured revolving credit facility.
Read in the 10-Q ↗
Item 1A of the 10-Q filed Nov 10, 2026 against Item 1A of the 10-K filed Feb 24, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted and underlined).
Text on the page, not a score; each links to the filing at sec.gov.
